Founded in 2015, Montreal-based Inversago Pharma is a leader in the development of next-generation CB1 receptor blocker therapies designed to treat obesity, diabetes, and the complications associated with an array of metabolic disorders.
July 15, 2024
Founded in 2015, Montreal-based Inversago Pharma is a leader in the development of next-generation CB1 receptor blocker therapies designed to treat obesity, diabetes, and the complications associated with an array of metabolic disorders.
Venture Ontario
Suite 3001
250 Yonge St.
Toronto, ON M5B 2L7
